Glycan Supplementation on a Human Model of Crohn's Disease Initiation and Progression

Who May Qualify: - Male or female between 18 and 75 years old (inclusive) able to provide oral and written willing to sign a consent form for participation in the study - Confirmed diagnosis of ileal or ileocolonic CD (according to ECCO guidelines) - Patients submitted to ileal and ileocecal resection for removing the diseased segment of the bowel. Who Should NOT Join This Trial: - Diagnosis of indeterminate colitis, ulcerative colitis or microscopic colitis (collagenous colitis or lymphocytic colitis) - Patients receiving antibiotics, aminosalicylates, thiopurines, methotrexate, biologics or small molecules after surgery for postoperative recurrence - Patients with previous ICR or ileal resection due to CD, unless the treating physician does not intend to start other prophylactic therapy apart from the glycan supplement within the first 6 months following surgery - Pregnant or lactating women - Documented allergy to shellfish, glycans or glycans derivatives - History of dysplasia on colonic biopsy - Presence of, or history of cancer, except for skin cancer - History of poorly controlled type 1 or type 2 diabetes (HbA1c\>8% or recurrent episodes of hyperglycaemic crisis such as diabetic ketoacidosis or hyperglycaemic hyperosmolar state) - Patients with known bleeding disorders (e.g. haemophilia or thrombocytopenia) or anticoagulation therapy (e.g. warfarin or direct oral anticoagulants) - Any physical or mental condition which would interfere with the ability to provide written and oral free willing to sign a consent form or limit the study participation, collection of data, or study completion as determined by the Investigator - Unwillingness or inability to follow the procedures outlined in the protocol. Always talk to your doctor about whether this trial is right for you.